What is Amdocs Limited's earnings per share (EPS)?

Amdocs Limited (DOX) reported diluted earnings per share of $4.25 for fiscal year 2024. This represents a -5.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amdocs Limited (DOX) Financials

DOX

FY2024 annual

Revenue $5.0B +2.4% YoY

Net Income $493.2M -8.8% YoY

EPS (Diluted) $4.25 -5.3% YoY

Free Cash Flow $618.9M -11.4% YoY

Market Cap $6.1B as of Oct 13, 2026

Price / Sales 1.2x on $5.0B revenue, FY2024

Price / Earnings 12.4x on $493.2M net income, FY2024

Price / Book 1.8x on $3.5B equity, Q4 FY2024

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2024, ended Sep 30, 2024 Reported Dec 17, 2024 Currency USD FYE September

Newest figures come from the 10-K for FY2024, filed Dec 17, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DOX SEC filings page.

Amdocs Limited (DOX) reported $5.0B in revenue for fiscal year 2024, up 2.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DOX FY2024 2026-10-04

Amdocs converts revenue into cash reliably, but recent growth is reaching the income statement less efficiently as costs and obligations rise.

Revenue expanded through FY2024, yet operating margin fell to 12.6%, showing that growth is not flowing through to operating profit as efficiently. Gross margin remained near 35%, indicating direct delivery economics held while costs below gross profit absorbed more of the expansion.

FY2024 operating cash flow of $724M exceeded net income of $493M, so accounting profit translated into more cash than the bottom line alone suggests. Free cash flow of $619M after $105M of capital expenditures indicates that relatively little operating cash was consumed by annual reinvestment.

Debt stayed near $646M across FY2022-FY2024, so leverage did not drive the balance-sheet change. The current ratio fell from 1.6x to 1.2x; alongside recurring buybacks and rising dividends, that shows cash is being returned while the short-term liquidity cushion narrows.

Financial Health Signals

Financial health score pending refresh

We are recalculating Amdocs Limited's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Safe

3.94

Amdocs Limited scores 3.94, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Amdocs Limited passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.47x

For every $1 of reported earnings, Amdocs Limited generates $1.47 in operating cash flow ($724.4M OCF vs $493.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

18.02x

Amdocs Limited earns $18.02 in operating income for every $1 of interest expense ($628.6M vs $34.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.3B

YoY+1.7%

QoQ+1.1%

5Y CAGR+4.2%

10Y CAGR+3.5%

Amdocs Limited generated $1.3B in revenue in Q4 2024. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 1.1%.

Net Income

$86.4M

YoY-15.3%

QoQ-38.4%

5Y CAGR-6.7%

10Y CAGR-1.5%

Amdocs Limited reported $86.4M in net income in Q4 2024. This represents a decrease of 15.3% from the same quarter a year earlier. Against the prior quarter it is down 38.4%.

EPS (Diluted)

$0.76

YoY-11.6%

QoQ-37.2%

5Y CAGR-3.3%

10Y CAGR+1.9%

Amdocs Limited earned $0.76 per diluted share (EPS) in Q4 2024. This represents a decrease of 11.6% from the same quarter a year earlier. Against the prior quarter it is down 37.2%.

EBITDA

Not reported for Q4 2024.

Cash & Balance Sheet

Cash & Debt

$346.1M

YoY-33.5%

Amdocs Limited held $346.1M in cash against $646.3M in long-term debt as of Q4 2024.

Shares Outstanding

113M

YoY-3.8%

QoQ0.0%

Amdocs Limited had 113M shares outstanding in Q4 2024. This represents a decrease of 3.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q4 2024.

Dividends Per Share

Not reported for Q4 2024.

Margins & Returns

Operating Margin

8.9%

YoY-2.3pp

QoQ-5.2pp

5Y change-5.1pp

10Y change-5.1pp

Amdocs Limited's operating margin was 8.9% in Q4 2024, reflecting core business profitability. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.2 percentage points.

Net Margin

6.8%

YoY-1.4pp

QoQ-4.4pp

5Y change-5.0pp

10Y change-4.3pp

Amdocs Limited's net profit margin was 6.8% in Q4 2024, showing the share of revenue converted to profit. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.4 percentage points.

Return on Equity

2.5%

YoY-0.4pp

Amdocs Limited's ROE was 2.5% in Q4 2024, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q4 2024.

Capital Allocation

None of these metrics is reported for Q4 2024.

DOX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOX quarterly income statement

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	$5.0B+2.4%	$4.9B+6.8%	$4.6B+6.7%	$4.3B+2.9%	$4.2B+2.0%	$4.1B+2.8%	$4.0B+2.8%	$3.9B+4.0%	$3.7B+2.0%	$3.6B+2.2%	$3.6B+6.5%	$3.3B+7.0%	$3.1B+2.2%	$3.1B+6.1%	$2.9B
Cost of Revenue	$3.2B+2.8%	$3.2B+6.8%	$3.0B+5.2%	$2.8B+2.0%	$2.8B+3.9%	$2.7B+2.2%	$2.6B+3.5%	$2.5B+4.1%	$2.4B+2.5%	$2.3B+1.8%	$2.3B+6.5%	$2.2B	N/A	N/A	N/A
Gross Profit	$1.8B+1.6%	$1.7B+6.7%	$1.6B+9.6%	$1.5B+4.5%	$1.4B-1.4%	$1.4B+3.9%	$1.4B+1.5%	$1.4B+3.8%	$1.3B+1.2%	$1.3B+3.0%	$1.3B+6.6%	$1.2B	N/A	N/A	N/A
SG&A Expenses	$572.8M+0.4%	$570.7M+8.0%	$528.6M+8.5%	$487.3M+6.3%	$458.5M-6.9%	$492.5M+2.4%	$481.1M+1.8%	$472.8M+1.7%	$464.9M+5.6%	$440.1M-1.1%	$445.1M+6.3%	$418.6M-1.4%	$424.7M+3.7%	$409.5M+9.6%	$373.6M
Operating Income	$628.6M-3.9%	$654.0M-1.6%	$664.8M+11.0%	$598.7M+0.7%	$594.8M+4.4%	$569.7M+33.0%	$428.3M-17.2%	$517.3M+7.1%	$483.1M-6.4%	$515.9M+4.1%	$495.6M+2.9%	$481.6M+8.8%	$442.5M+9.4%	$404.4M-1.5%	$410.4M
EBITDA	$819.5M-2.3%	$839.2M-5.6%	$889.3M+10.1%	$807.5M+1.8%	$793.2M+2.3%	$775.5M+21.3%	$639.5M-12.7%	$732.2M+5.4%	$694.9M+0.6%	$690.7M+4.9%	$658.4M+5.8%	$622.3M+3.4%	$602.1M+2.8%	$585.8M-3.4%	$606.4M
Interest Expense	$34.9M+51.1%	$23.1M+36.6%	$16.9M-20.5%	$21.3M+104.0%	$10.4M+166.6%	$3.9M+41.5%	$2.8M+72.8%	$1.6M-4.0%	$1.7M-46.9%	$3.1M-9.8%	$3.5M-2.1%	$3.6M+12.0%	$3.2M+10.2%	$2.9M-8.1%	$3.1M
Income Tax	$94.8M+1.4%	$93.4M-5.6%	$98.9M-21.5%	$125.9M+47.3%	$85.5M-3.3%	$88.4M+31.7%	$67.1M-11.8%	$76.1M+1.0%	$75.4M+12.1%	$67.2M-0.3%	$67.4M+7.0%	$63.0M+25.7%	$50.2M+2.3%	$49.0M+18.5%	$41.4M
Net Income	$493.2M-8.8%	$540.7M-1.6%	$549.5M-20.2%	$688.4M+38.3%	$497.8M+3.8%	$479.4M+35.3%	$354.4M-18.9%	$436.8M+6.7%	$409.3M-8.3%	$446.2M+5.7%	$422.1M+2.3%	$412.4M+5.4%	$391.4M+12.9%	$346.7M+0.8%	$343.9M
EPS (Basic)	$4.27-5.5%	$4.52+1.1%	$4.47-16.6%	$5.36+43.7%	$3.73+6.9%	$3.49+40.2%	$2.49-16.7%	$2.99+9.1%	$2.74-5.2%	$2.89+9.1%	$2.65+3.5%	$2.56+9.9%	$2.33+24.6%	$1.87+10.0%	$1.70
EPS (Diluted)	$4.25-5.3%	$4.49+1.1%	$4.44-16.5%	$5.32+43.4%	$3.71+6.9%	$3.47+40.5%	$2.47-16.6%	$2.96+9.2%	$2.71-4.9%	$2.85+8.8%	$2.62+3.6%	$2.53+9.5%	$2.31+24.2%	$1.86+10.1%	$1.69
Diluted Shares (Avg)	N/A	118M-2.8%	122M-4.8%	128M-4.0%	133M-2.9%	137M-3.8%	143M-2.5%	146M-2.4%	150M-3.4%	155M-2.7%	160M-2.2%	163M-3.7%	169M-9.2%	187M-8.6%	204M

Metric	Q4'2410-K	Q3'2410-K	Q2'2410-K	Q1'2410-K	Q4'2310-K	Q3'2310-K	Q2'2310-K	Q1'2310-K
Revenue	$1.3B+1.7%	$1.3B+1.1%	$1.2B+1.8%	$1.2B+5.0%	$1.2B+6.5%	$1.2B+6.5%	$1.2B+6.8%	$1.2B+7.3%
Operating Income	$112.7M-18.9%	$175.9M-3.7%	$155.7M-14.6%	$184.3M+22.8%	$138.9M-19.1%	$182.7M+7.9%	$182.3M+11.4%	$150.1M-6.3%
Net Income	$86.4M-15.3%	$140.3M-12.0%	$118.5M-20.8%	$148.0M+14.1%	$102.0M-20.9%	$159.4M+24.1%	$149.6M-5.6%	$129.7M-2.9%
EPS (Basic)	$0.76-11.6%	$1.22-8.3%	$1.02-17.7%	$1.27+18.7%	$0.86-18.9%	$1.33+26.7%	$1.24-3.9%	$1.070.0%
EPS (Diluted)	$0.76-11.6%	$1.21-8.3%	$1.01-17.9%	$1.26+17.8%	$0.86-18.1%	$1.32+26.9%	$1.23-3.9%	$1.070.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, EBITDA, Interest Expense, Income Tax, Diluted Shares (Avg).

DOX Balance Sheet

DOX quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$6.4B-0.6%	$6.4B+0.6%	$6.4B-1.9%	$6.5B+2.7%	$6.3B+19.8%	$5.3B-1.0%	$5.3B+1.3%	$5.3B-1.0%	$5.3B+0.1%	$5.3B+2.7%	$5.2B+5.3%	$4.9B+6.0%	$4.6B+0.2%	$4.6B-3.8%	$4.8B
Current Assets	$1.8B-7.3%	$1.9B-4.6%	$2.0B-3.1%	$2.1B-0.3%	$2.1B+23.8%	$1.7B-2.6%	$1.7B-16.0%	$2.0B-2.5%	$2.1B-11.7%	$2.4B-1.9%	$2.4B+6.2%	$2.3B+11.8%	$2.0B+3.1%	$2.0B-12.1%	$2.3B
Cash & Equivalents	$346.1M-33.5%	$520.1M-9.3%	$573.4M-19.1%	$709.1M-27.9%	$983.2M+108.5%	$471.6M+12.6%	$418.8M-35.5%	$649.6M-15.5%	$768.7M-25.8%	$1.0B-6.1%	$1.1B+8.8%	$1.0B+15.4%	$879.2M+5.7%	$831.4M-19.8%	$1.0B
Short-Term Investments	$168.2M-24.4%	$222.5M-9.1%	$244.6M-4.6%	$256.5M+34012.6%	$752K	$0-100.0%	$100.4M-69.6%	$330.0M+0.9%	$327.1M+2.7%	$318.4M-0.9%	$321.2M+2.9%	$312.2M+30.6%	$239.0M-30.1%	$342.1M-13.9%	$397.1M
Accounts Receivable	$1.0B+8.9%	$944.5M-0.2%	$946.8M+9.2%	$866.8M+0.7%	$861.0M-12.8%	$987.9M+1.7%	$971.5M+12.3%	$865.1M+5.7%	$818.5M+14.5%	$714.8M-0.1%	$715.8M+5.5%	$678.2M-1.3%	$687.2M+21.4%	$565.9M-2.4%	$580.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$2.8B+3.5%	$2.7B+3.2%	$2.7B+1.5%	$2.6B+1.7%	$2.6B+4.7%	$2.5B+0.7%	$2.4B+10.1%	$2.2B+0.4%	$2.2B+7.9%	$2.0B+6.4%	$1.9B+5.9%	$1.8B+4.4%	$1.7B+0.1%	$1.7B+6.2%	$1.6B
Total Liabilities	$2.9B+1.0%	$2.9B+1.0%	$2.8B-1.6%	$2.9B+7.5%	$2.7B+52.9%	$1.8B-5.7%	$1.9B+8.8%	$1.7B-9.2%	$1.9B-2.1%	$1.9B+7.2%	$1.8B+8.4%	$1.7B+2.4%	$1.6B-0.1%	$1.6B+1.4%	$1.6B
Current Liabilities	$1.5B+8.7%	$1.4B+8.0%	$1.3B-3.9%	$1.3B+7.2%	$1.2B+0.7%	$1.2B-6.7%	$1.3B+10.4%	$1.2B-14.1%	$1.4B+0.2%	$1.4B+13.6%	$1.2B+11.8%	$1.1B+0.8%	$1.1B+5.4%	$1.0B-1.3%	$1.0B
Non-Current Liabilities	$1.4B-5.9%	$1.5B-4.6%	$1.6B+0.3%	$1.6B+7.7%	$1.5B+169.2%	$542.4M-3.3%	$560.8M+5.3%	$532.4M+4.0%	$511.8M-7.7%	$554.3M-5.8%	$588.7M+2.1%	$576.8M+5.5%	$546.5M-9.2%	$602.1M+6.2%	$567.1M
Long-Term Debt	$646.3M+0.1%	$645.7M+0.1%	$645.1M+0.1%	$644.6M+0.1%	$644.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.5B-1.9%	$3.5B+0.2%	$3.5B-2.1%	$3.6B-0.8%	$3.6B+3.5%	$3.5B+1.5%	$3.4B-3.5%	$3.6B+3.5%	$3.5B+1.4%	$3.4B+0.3%	$3.4B+3.7%	$3.3B+8.0%	$3.0B+0.3%	$3.0B-6.4%	$3.2B
Retained Earnings	$6.8B+4.2%	$6.5B+5.4%	$6.2B+6.2%	$5.9B+9.5%	$5.3B+6.6%	$5.0B+7.3%	$4.7B+4.9%	$4.5B+7.5%	$4.1B+7.7%	$3.8B+9.8%	$3.5B+10.3%	$3.2B+11.5%	$2.8B+14.9%	$2.5B+16.3%	$2.1B

Metric	Q4'2410-K	Q3'2410-K	Q2'2410-K	Q1'2410-K	Q4'2310-K	Q3'2310-K	Q2'2310-K	Q1'2310-K
Total Assets	$6.4B-0.6%	N/A	N/A	N/A	$6.4B+0.6%	N/A	N/A	N/A
Current Assets	$1.8B-7.3%	N/A	N/A	N/A	$1.9B-4.6%	N/A	N/A	N/A
Cash & Equivalents	$346.1M-33.5%	N/A	N/A	N/A	$520.1M-9.3%	N/A	N/A	N/A
Short-Term Investments	$168.2M-24.4%	N/A	N/A	N/A	$222.5M-9.1%	N/A	N/A	N/A
Accounts Receivable	$1.0B+8.9%	N/A	N/A	N/A	$944.5M-0.2%	N/A	N/A	N/A
Long-Term Investments	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Goodwill	$2.8B+3.5%	N/A	N/A	N/A	$2.7B+3.2%	N/A	N/A	N/A
Total Liabilities	$2.9B+1.0%	N/A	N/A	N/A	$2.9B+1.0%	N/A	N/A	N/A
Current Liabilities	$1.5B+8.7%	N/A	N/A	N/A	$1.4B+8.0%	N/A	N/A	N/A
Non-Current Liabilities	$1.4B-5.9%	N/A	N/A	N/A	$1.5B-4.6%	N/A	N/A	N/A
Long-Term Debt	$646.3M+0.1%	N/A	N/A	N/A	$645.7M+0.1%	N/A	N/A	N/A
Total Equity	$3.5B-1.9%	N/A	N/A	N/A	$3.5B+0.2%	N/A	N/A	N/A
Retained Earnings	$6.8B+4.2%	N/A	N/A	N/A	$6.5B+5.4%	N/A	N/A	N/A

Not reported in any period shown, so not listed: Inventory.

DOX Cash Flow Statement

DOX quarterly cash flow statement

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	$724.4M-11.9%	$822.6M+8.7%	$756.7M-18.3%	$925.8M+40.7%	$658.1M+0.3%	$656.4M+17.8%	$557.2M-12.4%	$636.1M+2.6%	$620.2M-19.7%	$772.6M+8.9%	$709.3M+5.8%	$670.5M+30.4%	$514.1M-4.0%	$535.5M-21.8%	$685.2M
Depreciation & Amortization	$190.9M+3.1%	$185.2M-17.5%	$224.5M+7.5%	$208.8M+5.3%	$198.4M-3.6%	$205.8M-2.6%	$211.2M-1.7%	$214.9M+1.5%	$211.8M+21.2%	$174.8M+7.4%	$162.8M+15.6%	$140.8M-11.8%	$159.6M-12.0%	$181.5M-7.4%	$195.9M
Stock-Based Compensation	$104.5M+16.5%	$89.7M+24.9%	$71.8M+32.4%	$54.2M+27.8%	$42.4M+10.1%	$38.5M-18.8%	$47.5M+6.6%	$44.5M+4.3%	$42.7M-4.2%	$44.6M0.0%	$44.6M+10.5%	$40.3M-7.1%	$43.4M+18.6%	$36.6M-17.6%	$44.5M
Capital Expenditures	$105.5M-15.2%	$124.4M-45.3%	$227.2M+8.0%	$210.4M	N/A	N/A	$231.1M+73.3%	$133.4M+2.5%	$130.1M+8.0%	$120.5M+8.0%	$111.6M+4.5%	$106.7M-12.6%	$122.1M+11.2%	$109.8M+26.3%	$86.9M
Free Cash Flow	$618.9M-11.4%	$698.3M+31.9%	$529.5M-26.0%	$715.4M	N/A	N/A	$326.1M-35.1%	$502.7M+2.6%	$490.1M-24.8%	$652.1M+9.1%	$597.7M+6.0%	$563.8M+43.8%	$392.0M-7.9%	$425.7M-28.8%	$598.3M
Investing Cash Flow	-$127.4M+43.2%	-$224.5M+14.5%	-$262.5M+20.2%	-$329.0M+28.7%	-$461.7M-432.2%	-$86.8M+76.1%	-$362.4M-95.6%	-$185.3M+58.0%	-$440.9M	N/A	N/A	-$297.1M-1618.6%	-$17.3M+92.2%	-$221.7M-4.8%	-$211.5M
Financing Cash Flow	-$771.0M-18.4%	-$651.4M-3.4%	-$629.9M+27.7%	-$870.9M-376.4%	$315.1M+161.0%	-$516.8M-21.4%	-$425.7M+25.3%	-$569.8M-27.7%	-$446.3M	N/A	N/A	-$238.4M+46.9%	-$449.0M+13.4%	-$518.6M-212.0%	-$166.3M
Dividends Paid	$212.0M+6.3%	$199.5M+7.2%	$186.1M+4.8%	$177.5M+8.2%	$164.1M+11.1%	$147.6M+9.9%	$134.3M+10.5%	$121.5M+11.2%	$109.3M+8.4%	$100.8M+10.8%	$90.9M+8.3%	$84.0M	N/A	N/A	N/A
Share Buybacks	$563.1M+15.0%	$489.5M-3.7%	$508.5M-25.2%	$680.0M+88.4%	$360.9M-9.3%	$398.1M-5.0%	$419.2M+23.1%	$340.6M-17.6%	$413.4M-8.9%	$454.0M+22.0%	$372.0M+1.3%	$367.1M-24.3%	$484.6M-22.4%	$624.2M+60.4%	$389.3M

Metric	Q4'2410-K	Q3'2410-K	Q2'2410-K	Q1'2410-K	Q4'2310-K	Q3'2310-K	Q2'2310-K	Q1'2310-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

DOX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOX quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Gross Margin	35.1%-0.3pp	35.4%0.0pp	35.4%+0.9pp	34.5%+0.6pp	33.9%-1.2pp	35.1%+0.4pp	34.7%-0.5pp	35.2%-0.1pp	35.2%-0.3pp	35.5%+0.3pp	35.3%0.0pp	35.2%	N/A	N/A	N/A
Operating Margin	12.6%-0.8pp	13.4%-1.2pp	14.5%+0.6pp	14.0%-0.3pp	14.3%+0.3pp	13.9%+3.2pp	10.8%-2.6pp	13.4%+0.4pp	13.0%-1.2pp	14.2%+0.3pp	13.9%-0.5pp	14.4%+0.2pp	14.1%+0.9pp	13.2%-1.0pp	14.2%
Net Margin	9.8%-1.2pp	11.1%-0.9pp	12.0%-4.0pp	16.1%+4.1pp	11.9%+0.2pp	11.7%+2.8pp	8.9%-2.4pp	11.3%+0.3pp	11.0%-1.2pp	12.3%+0.4pp	11.8%-0.5pp	12.3%-0.2pp	12.5%+1.2pp	11.3%-0.6pp	11.9%
Return on Equity	14.3%-1.1pp	15.3%-0.3pp	15.6%-3.5pp	19.2%+5.4pp	13.7%0.0pp	13.7%+3.4pp	10.3%-1.9pp	12.2%+0.4pp	11.8%-1.3pp	13.1%+0.7pp	12.4%-0.2pp	12.6%-0.3pp	12.9%+1.4pp	11.5%+0.8pp	10.7%
Return on Assets	7.7%-0.7pp	8.4%-0.2pp	8.6%-2.0pp	10.6%+2.7pp	7.8%-1.2pp	9.1%+2.4pp	6.6%-1.6pp	8.3%+0.6pp	7.7%-0.7pp	8.4%+0.2pp	8.1%-0.2pp	8.4%-0.1pp	8.4%+0.9pp	7.5%+0.4pp	7.1%
Current Ratio	1.20-0.2x	1.41-0.2x	1.600.0x	1.59-0.1x	1.71+0.3x	1.39+0.1x	1.33-0.4x	1.75+0.2x	1.54-0.2x	1.74-0.3x	2.02-0.1x	2.12+0.2x	1.920.0x	1.96-0.2x	2.20
Debt-to-Equity	0.190.0x	0.180.0x	0.180.0x	0.180.0x	0.18-0.3x	0.500.0x	0.54+0.1x	0.48-0.1x	0.540.0x	0.560.0x	0.530.0x	0.500.0x	0.530.0x	0.530.0x	0.49
Asset Turnover	0.780.0x	0.760.0x	0.72+0.1x	0.660.0x	0.66-0.1x	0.770.0x	0.740.0x	0.730.0x	0.700.0x	0.680.0x	0.690.0x	0.680.0x	0.670.0x	0.66+0.1x	0.60
FCF Margin	12.4%-1.9pp	14.3%+2.7pp	11.6%-5.1pp	16.7%	N/A	N/A	8.2%-4.8pp	13.0%-0.2pp	13.2%-4.7pp	17.9%+1.1pp	16.8%-0.1pp	16.9%+4.3pp	12.5%-1.4pp	13.9%-6.8pp	20.8%

Metric	Q4'2410-K	Q3'2410-K	Q2'2410-K	Q1'2410-K	Q4'2310-K	Q3'2310-K	Q2'2310-K	Q1'2310-K
Operating Margin	8.9%-2.3pp	14.1%-0.7pp	12.5%-2.4pp	14.8%+2.1pp	11.2%-3.5pp	14.8%+0.2pp	14.9%+0.6pp	12.7%-1.8pp
Net Margin	6.8%-1.4pp	11.2%-1.7pp	9.5%-2.7pp	11.9%+0.9pp	8.2%-2.8pp	12.9%+1.8pp	12.2%-1.6pp	10.9%-1.1pp
Return on Equity	2.5%-0.4pp	N/A	N/A	N/A	2.9%-0.8pp	N/A	N/A	N/A
Return on Assets	1.4%-0.2pp	N/A	N/A	N/A	1.6%-0.4pp	N/A	N/A	N/A
Current Ratio	1.20-0.2x	N/A	N/A	N/A	1.41-0.2x	N/A	N/A	N/A
Debt-to-Equity	0.190.0x	N/A	N/A	N/A	0.180.0x	N/A	N/A	N/A
Asset Turnover	0.200.0x	N/A	N/A	N/A	0.190.0x	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Amdocs Limited DOX	FY2024	$5.0B	$493.2M	9.8%	$6.1B	—
Klaviyo, Inc. KVYO	FY2025	$1.2B	-$31.8M	-2.6%	$4.9B	63/100
WIX.com Ltd. WIX	FY2025	$2.0B	$50.6M	2.5%	$3.1B	30/100
Dropbox, Inc. DBX	FY2025	$2.5B	$508.4M	20.2%	$7.6B	50/100
GitLab Inc. GTLB	FY2026	$955.2M	-$58.6M	-6.1%	$9.3B	56/100
Informatica Inc. INFA	FY2024	$1.6B	$9.9M	0.6%	$7.6B	48/100

Where Amdocs Limited Ranks

Frequently Asked Questions

What is Amdocs Limited's annual revenue?

Amdocs Limited (DOX) reported $5.0B in total revenue for fiscal year 2024. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amdocs Limited's revenue growing?

Amdocs Limited (DOX) revenue grew by 2.4% year-over-year, from $4.9B to $5.0B in fiscal year 2024.

Is Amdocs Limited profitable?

Yes, Amdocs Limited (DOX) reported a net income of $493.2M in fiscal year 2024, with a net profit margin of 9.8%.

What is Amdocs Limited's EBITDA?

Amdocs Limited (DOX) had EBITDA of $819.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Amdocs Limited have?

As of fiscal year 2024, Amdocs Limited (DOX) had $346.1M in cash and equivalents against $646.3M in long-term debt.

What is Amdocs Limited's gross margin?

Amdocs Limited (DOX) had a gross margin of 35.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Amdocs Limited's operating margin?

Amdocs Limited (DOX) had an operating margin of 12.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Amdocs Limited's net profit margin?

Amdocs Limited (DOX) had a net profit margin of 9.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Does Amdocs Limited pay dividends?

Yes, Amdocs Limited (DOX) paid $1.87 per share in dividends during fiscal year 2024.

What is Amdocs Limited's return on equity (ROE)?

Amdocs Limited (DOX) has a return on equity of 14.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Amdocs Limited's free cash flow?

Amdocs Limited (DOX) generated $618.9M in free cash flow during fiscal year 2024. This represents a -11.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amdocs Limited's operating cash flow?

Amdocs Limited (DOX) generated $724.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Amdocs Limited's total assets?

Amdocs Limited (DOX) had $6.4B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Amdocs Limited's capital expenditures?

Amdocs Limited (DOX) invested $105.5M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Does Amdocs Limited buy back shares?

Yes, Amdocs Limited (DOX) spent $563.1M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Amdocs Limited have outstanding?

Amdocs Limited (DOX) had 113M shares outstanding as of fiscal year 2024.

What is Amdocs Limited's current ratio?

Amdocs Limited (DOX) had a current ratio of 1.20 as of fiscal year 2024, which is considered adequate.

What is Amdocs Limited's debt-to-equity ratio?

Amdocs Limited (DOX) had a debt-to-equity ratio of 0.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Amdocs Limited's return on assets (ROA)?

Amdocs Limited (DOX) had a return on assets of 7.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Amdocs Limited's P/E ratio?

Amdocs Limited (DOX) trades at 12.4x earnings, its market capitalization divided by net income of $493.2M net income, FY2024. The market capitalization is $6.1B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amdocs Limited's price-to-sales ratio?

Amdocs Limited (DOX) trades at 1.2x sales, its market capitalization divided by revenue of $5.0B revenue, FY2024. The market capitalization is $6.1B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amdocs Limited's Altman Z-Score?

Amdocs Limited (DOX) has an Altman Z-Score of 3.94, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Amdocs Limited's Piotroski F-Score?

Amdocs Limited (DOX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amdocs Limited's earnings high quality?

Amdocs Limited (DOX) has an earnings quality ratio of 1.47x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Amdocs Limited cover its interest payments?

Amdocs Limited (DOX) has an interest coverage ratio of 18.02x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.